Redhill Biopharma RDHL shares are trading higher on Friday, after the company received FDA approval for its coronavirus clinical study with Opaganib in the U.S.
Redhill Biopharma is a specialty company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults.
Redhill Biopharma shares were trading up 7.86% at $7.05 at time of publication. The stock has a 52-week high of $9.12 and a 52-week low of $3.26.
Related Links:
Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
